Talk to Sam
+1 718 473 0872
... Briggs et al amj 2012] upskilling consumers and health professionals [briggs et al. Bmc health serv res 2012; slater et al. Bmc musculoskelet disord. 2012; Slater et al. Plos one, 2012; slater et al ...
» Purchase Premium Reports (From $ 99 - $ 11 400)About 13 000 reports for Musculoskeletal Disorder
Scope Just over a year ago - and buoyed by recent FDA approval - expectations for Pfizer's rheumatoid arthritis treatment Xeljanz (tofacitinib) were suitably high. The drug - an oral alternative to injectable ...
Reportlinker.com © Copyright 2013. All rights reserved.